Today we’re announcing the close of our $350M Series A, bringing Lila’s total capital raised to $550M. We’re using this financing to accelerate the buildout of our AI Science Factories and bring our scientific superintelligence platform to customers working on the world’s hardest problems. Lila Sciences emerged from two years in stealth in March with a singular mission: build scientific superintelligence to solve humankind’s greatest challenges. That requires sleeves‑roll

Trial initiation follows the recent approval of IBTROZI™ (taletrectinib) for locally advanced or metastatic ROS1-positive non-small cell...